Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Last trade$0.3373
Day change-$0.0155 (-4.39%)
Day range$0.326 – $0.359
Volume1,918,259
Market cap$38M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$37.81M
Price / earnings
—
Price / book
0.49×
Price / sales
4×
EV / sales
1.24×
EV / EBITDA
-0.11×
Profitability
Earnings per share
-$0.95
Return on assets
-83.41%
Return on equity
-133.91%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.97×
Quick ratio
4.97×
Cash ratio
1.29×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$93.24M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CRBU, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.61M
$1.5M
$2.4M
$3.94M
$2.2M
$2.67M
$2.35M
$2.08M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.61M
$1.5M
$2.4M
$3.94M
$2.2M
$2.67M
$2.35M
$2.08M
Selling, general and administrative
$7.9M
$7.9M
$8.07M
$8.58M
$9.2M
$10.4M
$9.74M
$10.49M
Research and development
$21.35M
$18.94M
$20.61M
$23.82M
$22.4M
$27.69M
$35.53M
$30.46M
Total operating expenses
$29.25M
$26.84M
$28.68M
$32.39M
$31.6M
$50.25M
$45.27M
$40.95M
Operating income
-$27.64M
-$25.34M
-$26.28M
-$28.45M
-$29.4M
-$47.58M
-$42.91M
-$38.88M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$26.61M
-$24.28M
-$25.09M
-$27.04M
-$27.55M
-$54.1M
-$39.99M
-$35.5M
Income taxes
$0
$0
$0
-$550K
$0
$0
$0
-$9K
Net income
-$26.61M
-$24.28M
-$25.09M
-$26.49M
-$27.55M
-$54.1M
-$39.99M
-$35.49M
Net income attributable to common shareholders
-$26.61M
-$24.28M
-$25.09M
-$26.64M
-$27.55M
-$54.1M
-$39.99M
-$35.27M
EBITDA
-$27.05M
-$24.71M
-$25.63M
-$27.77M
-$28.77M
-$34.26M
-$41.75M
-$37.69M
Basic earnings per share
-$0.25
-$0.24
-$0.26
-$0.28
-$0.30
-$0.58
-$0.43
-$0.39
Diluted earnings per share
-$0.25
-$0.24
-$0.26
-$0.28
-$0.30
-$0.58
-$0.43
-$0.39
Recent news
Company coverage with links to the original publishers.
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
Caribou Biosciences (CRBU) has formed a hammer chart pattern after a 12.1% decline over the past week, suggesting a potential trend reversal. The technical indicator is supported by fundamental strength, including an 11.7% increase in consensus EPS estimates over the last 30 days and a Zacks Rank #2 (Buy) rating, indicating analyst agreement on improved earnings prospects.
Caribou Biosciences reported a Q3 loss of $0.25 per share, beating consensus estimates of $0.27 loss, with a 7.41% earnings surprise. Revenue came in at $1.61 million, surpassing estimates by 7.13%, though down from $2.2 million year-ago. The stock has declined 72.1% year-to-date and carries a Zacks Rank #2 (Buy) rating based on favorable estimate revisions.
Castle Biosciences reported a Q3 loss of $0.13 per share, beating consensus estimates of $0.38 loss by 65.79%. Revenue reached $102.89 million, surpassing estimates by 11.84% and growing 23.9% year-over-year. The company has beaten consensus estimates four consecutive quarters. However, CSTL shares have underperformed the market, down 8.1% year-to-date versus S&P 500's 12.3% gain. The stock received a Zacks Rank #3 (Hold) rating, expected to perform in line with the market.
Caribou Biosciences is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +7.41% and Zacks Rank #2 (Buy). The company is projected to report a quarterly loss of $0.27 per share (improved 10% YoY) on revenues of $1.5 million (down 31.8% YoY). With a strong history of beating consensus estimates in the last four quarters, the stock appears positioned for a potential positive price movement.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.